2010
Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells
Grigoriadis AE, Kennedy M, Bozec A, Brunton F, Stenbeck G, Park IH, Wagner EF, Keller GM. Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells. Blood 2010, 115: 2769-2776. PMID: 20065292, PMCID: PMC2854424, DOI: 10.1182/blood-2009-07-234690.Peer-Reviewed Original ResearchConceptsPluripotent stem cellsInduced pluripotent stem cellsStem cellsPrimitive streak-like populationHuman pluripotent stem cellsHuman cell typesEmbryonic bone developmentEmbryoid bodiesBone-resorbing osteoclastsMacrophage colony-stimulating factorIPS cellsHematopoietic cytokinesCell typesMolecular analysisCathepsin KHuman ESHematopoietic precursorsPrecursor populationAlphavbeta3 integrinBone developmentConfocal microscopyAbsence of RANKLNuclear factor-kappaB ligandDisease mechanismsSerum-free medium
2009
Dominant role of CD47–thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease
Kukreja A, Radfar S, Sun BH, Insogna K, Dhodapkar MV. Dominant role of CD47–thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease. Blood 2009, 114: 3413-3421. PMID: 19661269, PMCID: PMC2765677, DOI: 10.1182/blood-2009-03-211920.Peer-Reviewed Original ResearchConceptsHuman dendritic cellsDendritic cellsBone diseaseOsteoclast formationRecruitment of DCsTumor cellsThrombospondin-1Regulation of CD47Tumor-associated osteoclastsNuclear factor-kappaB ligandMyeloma bone diseaseLytic bone diseasePrimary myeloma cellsHuman osteoclast formationMyeloma cell linesParathyroid hormoneKappaB ligandReceptor activatorOsteoclast precursorsGiant cellsSpontaneous cell-cell fusionMyeloma cellsHuman monocytesMyeloma tumorsDisease
2007
The Role of the Receptor Activator of Nuclear Factor-κB Ligand/Osteoprotegerin Cytokine System in Primary Hyperparathyroidism
Nakchbandi IA, Lang R, Kinder B, Insogna KL. The Role of the Receptor Activator of Nuclear Factor-κB Ligand/Osteoprotegerin Cytokine System in Primary Hyperparathyroidism. The Journal Of Clinical Endocrinology & Metabolism 2007, 93: 967-973. PMID: 18073309, PMCID: PMC2266956, DOI: 10.1210/jc.2007-1645.Peer-Reviewed Original ResearchConceptsNuclear factor-kappaB ligandPrimary hyperparathyroidismBone lossReceptor activatorTotal femurIL-6Bone resorptionIL-6 soluble receptorMild primary hyperparathyroidismBone mineral densitySoluble receptor activatorMechanism of actionIL-6sRSRANKL levelsSerum levelsBone turnoverMineral densityCytokine systemSoluble receptorHyperparathyroidismNormal rangeSkeletal responsivenessBiochemical markersPatientsGreater riskTargeted Deletion of a Distant Transcriptional Enhancer of the Receptor Activator of Nuclear Factor-κB Ligand Gene Reduces Bone Remodeling and Increases Bone Mass
Galli C, Zella LA, Fretz JA, Fu Q, Pike JW, Weinstein RS, Manolagas SC, O’Brien C. Targeted Deletion of a Distant Transcriptional Enhancer of the Receptor Activator of Nuclear Factor-κB Ligand Gene Reduces Bone Remodeling and Increases Bone Mass. Endocrinology 2007, 149: 146-153. PMID: 17932217, PMCID: PMC2194617, DOI: 10.1210/en.2007-0734.Peer-Reviewed Original ResearchConceptsBone massRANKL expressionReceptor activatorRANKL mRNAIncreases bone massNuclear factor-kappaB ligandPrimary bone marrow cultures
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply